Skip to main content

Table 4 OS and PFS (all patients)

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

  Median OS (months) Median PFS (months)
Protein Expression Low High P-value Low High P-value
 ERCC1 21.4 10.5 0.006 10.2 5.1 0.027
 COX2 17.7 10.5 0.051 6.5 5.2 0.463
 Tubulin B3 11.6 11.9 0.704 6 6 0.347
 CD4 11.9 11.9 0.446 5.6 8.8 0.253
 CD8 13.5 8.6 0.041 6 3.9 0.766
SNPs         
MDR1 C3435T CC TT CT P-value CC TT CT P-value
  20.2 16.5 10.5 0.19 7.9 6.6 6 0.654
MDR1 G2677 T GG TT GT   GG TT GT  
  8.6 3.6 17.7 0.119 5.1 2.9 8.6 0.027
ERCC1C8092A AA CC CA   AA CC CA  
  25.2 11.6 15.4 0.756 2.8 6 6 0.543
ERCC1 N118 N CC TT CT   CC TT CT  
  8.2 21.4 8.5 0.063 5.2 8.8 3.9 0.006